Back to Stakeholders

The American Psychiatric Association is the national medical specialty society for psychiatry in the United States, with headquarters in Washington, DC and a membership base of psychiatric physicians. It serves psychiatrists and the broader mental health field through official position statements, clinical guidance, journals, and public policy communications. Its core activity is to represent psychiatry in clinical, professional, and policy discussions affecting mental health care.

APA has an explicit, cautious stance on psychedelics and empathogens in mental health care. Its 2022 position statement says there is not yet adequate scientific evidence to endorse use outside approved investigational studies, while supporting continued research under strong scientific and regulatory standards. In 2024 APA also submitted comments to FDA on MDMA and in 2026 it publicly welcomed federal investment in psychedelic research while reiterating the need for controlled studies and patient protections.

Practitioner-Led Care Snapshot

Professional Associations

Organization Model

Professional Association

Organization Status

Active

Psychedelic Services

Active Psychedelic-Related Offering

Service Coverage

National

Care Profile

Care Modalities

Psychiatric Evaluation & ManagementReferral Navigation

Access Pathways

Licensed Medical Practice
Visit Provider

Status Notes

General psychiatric association profile verified; psychedelic-specific guidance linkage should be deepened in a follow-up evidence pass.

Quick Facts

Type
Non-Profit
HQ
United States
Website
Visit

Collaborated Trials

2